Capsugel today announced that it has
acquired Encap Drug Delivery. Based in Scotland, Encap’s focus on liquid
and semi-solid encapsulation-based product development, and clinical
and commercial manufacturing for the pharmaceutical industry,
complements Capsugel’s recently-established Dosage Form Solutions (DFS)
business unit which develops and manufactures innovative products for
the healthcare industry.
“Encap’s capabilities and offerings align
seamlessly with our DFS business unit which is focused on lipid-based
formulations and targeted release capsules,” says Guido Driesen,
President & CEO of Capsugel. “This acquisition will accelerate the
growth of DFS and further strengthen our leadership position in
liquid-filled formulations in hard capsules.”
Encap operates an FDA and MHRA inspected pharmaceutical product development and manufacturing site, is equipped to handle high potency active ingredients,
and has established a clinical fast-track program that can speed the
process from lab to clinic. Additionally, Encap’s proprietary targeted
release technologies (DuoCap™ and ENCODE®) and abuse deterrence technologies (Abusolve®) will add to Capsugel’s growing suite of offerings in these areas.
Capsugel DFS’s lipid-based technology platform currently includes proprietary Licaps® liquid-filled capsules, softgels,
solid-lipid pellets, and a lipid formulation software system aimed at
accelerating lipid-based product development for customers. The business
unit’s emerging targeted release technology platform includes
specialized capsules that enable different types and levels of
controlled release delivery.
No comments:
Post a Comment
Please share your views to enrich the discussion